208 related articles for article (PubMed ID: 26223310)
1. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Gissel C; Götz G; Mahlich J; Repp H
BMC Infect Dis; 2015 Jul; 15():297. PubMed ID: 26223310
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
4. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Perazzo H; Jorge MJ; Silva JC; Avellar AM; Silva PS; Romero C; Veloso VG; Mujica-Mota R; Anderson R; Hyde C; Castro R
BMC Gastroenterol; 2017 Nov; 17(1):119. PubMed ID: 29169329
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
7. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT
Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
Gandjour A
PLoS One; 2020; 15(10):e0236543. PubMed ID: 33006987
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
11. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].
Mar J; Mar-Barrutia L; Gimeno-Ballester V; San Miguel R
Med Clin (Barc); 2016 Jan; 146(2):61-4. PubMed ID: 26654558
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
[TBL] [Abstract][Full Text] [Related]
19. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD
Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
